JP MORGAN/CALL/BECTON DICKINSON AND CO./270/0.1/17.01.25 Share Price

Warrant

DE000JL1MHW7

Real-time Bid/Ask 02:38:26 03/06/2024 pm IST
1.03 EUR / 1.18 EUR +31.55% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./270/0.1/17.01.25
1 month-39.57%
3 months-56.25%
Date Price Change
03/24/03 1.06 +26.19%
31/24/31 0.84 +18.31%
30/24/30 0.71 -13.41%
29/24/29 0.82 -14.58%
28/24/28 0.96 +9.09%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 12:44 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL1MHW
ISINDE000JL1MHW7
Date issued 05/04/2023
Strike 270 $
Maturity 17/01/2025 (229 Days)
Parity 10 : 1
Emission price 2.48
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 5.68
Lowest since issue 0.71
Spread 0.15
Spread %12.61%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232 USD
Average target price
278.7 USD
Spread / Average Target
+20.14%
Consensus